Clinical trials: Antiplatelet Effect
Non-ST or ST Elevation Acute Coronary Syndromes
A Phase IV Study of the Onset and Maintenance of the Antiplatelet Effect of Ticagrelor Compared With Clopidogrel in Chinese Patients With ACS
The purpose of this study is to test the hypothesis that the onset of the antiplatelet effect of ticagrelor is more rapid and greater than clopidogrel in Chinese patients with ACS.
- Trial name
- HouYi (NCT01864005)
- Testing
- Ticagrelor, Clopidogrel
- Where
- 3 sites in China
- Volunteers
- 60 people
- Sponsor
- AstraZeneca
Healthy
The Antiplatelet and Immune Response Trial
Platelets are the main type of blood cell involved in the formation of blood clots that cause heart attacks. The investigators give antiplatelet drugs (aspirin, for example) to reduce the risk of another clot forming in the…
- Trial name
- NCT01846559
- Testing
- Endotoxin, Clopidogrel, Ticagrelor
- Where
- United Kingdom
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
Stable Angina
Antiplatelet and Anti-inflammatory Effects of Statins and Ezetimibe
Among patients with stable coronary artery disease (CAD), it is not clear if the pleiotropic effects of cholesterol reduction differ between high-dose simvastatin alone and combined ezetimibe/simvastatin.
- Trial name
- NCT00474123
- Testing
- Simvastatin 80 mg/day for 6 weeks, Ezetimibe 10 mg / Simvastatin 20 mg
- Where
- Brazil
- Volunteers
- 78 people
- Sponsor
- University of Sao Paulo
Anticoagulant Drugs, Antiplatelet Drug
Effect of Anticoagulant Drug Intervention on Postoperative MALE and MACE in Patients With PAD
Patients with PAD were grouped according to the combination of different anticoagulant and antiplate drugs. The type, dosage and duration of anticoagulant and antiplatelet drugs were recorded after operation.
- Conditions
- Anticoagulant Drugs, Antiplatelet Drug, Peripheral Arterial Disease
- Trial name
- NCT05852197
- Testing
- anticoagulant or antiplatelet drugs
- Where
- China
- Volunteers
- 6,000 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Coronary Artery Disease
Pharmacodynamic Effects of Atorvastatin vs. Rosuvastatin on Platelet Reactivity
Patients with coronary artery disease (CAD) are often treated with dual antiplatelet therapy (DAT), including aspirin and clopidogrel, to prevent from recurrent atherothrombotic events.
- Trial name
- PEARL (NCT01567774)
- Testing
- Atorvastatin, Rosuvastatin
- Where
- 2 sites in Italy
- Volunteers
- 100 people
- Sponsor
- University of Roma La Sapienza
Peripheral Artery Disease
Effects of Prolonged DAPT After Lower Extremity Percutaneous Transluminal Angioplasty (PTA) in Patients With LE-PAD
The objective of the present study was to evaluate the prognostic impact of prolonged dual antiplatelet therapy (DAPT) with acetylsalicylic acid plus clopidogrel on the incidence of major adverse cardiovascular events and major…
- Trial name
- LONGDAPTPAD (NCT02798913)
- Testing
- Short DAPT, Long DAPT
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- Federico II University
Coronary Artery Disease
Pharmacodynamic Effects of Prasugrel Compared With Ticagrelor in Patients With Coronary Artery Disease
Recently, two P2Y12 receptor inhibitors have been approved for clinical use: prasugrel and ticagrelor. Both prasugrel and ticagrelor have shown to be associated with more potent antiplatelet effects compared with clopidogrel and…
- Trial name
- NCT01852175
- Testing
- Prasugrel, Ticagrelor
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- University of Florida
Ischemic Stroke, Antiplatelet Effect
Double Randomized and Placebo Controlled Trail of Sanchitongshu Combined Antiplatelet Drug to Prevent Ischemic Stroke
This clinical trail will evaluate the effect of Sanchitongshu combined with antiplatelet drugs (Aspirin or Clopidogrel) in the treatment of high-risk ischemic stroke patients in adults.
- Trial name
- NCT04142151
- Testing
- Sanchitongshu, Aspirin, Clopidogrel
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Antiplatelet Effect
Study to Investigate Safety and Tolerability of a Single Dose of AZD6482
AZD6482 is a new drug substance aiming to prevent blood clots which may arise in atherosclerotic blood vessels and cause myocardial infarction or stroke. This is the first study with AZD6482 in humans.
- Trial name
- NCT00688714
- Testing
- AZD6482
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
HIV, Cardiovascular Diseases
Antiplatelet Therapy in HIV
The proposed study will add to the growing understanding of platelet activity and platelet inhibition in subjects with HIV. It will examine the relationship between platelet activity and its inhibition by antiplatelet therapy…
- Conditions
- HIV, Cardiovascular Diseases, Inflammation
- Trial name
- NCT02559414
- Testing
- Aspirin, Clopidogrel
- Where
- 2 sites in United States
- Volunteers
- 55 people
- Sponsor
- NYU Langone Health
Coronary Artery Disease
Reversing Ticagrelor's Effects With Fresh Platelets
Acute coronary syndrome (ACS) patients treated with antiplatelet drugs who require coronary artery bypass grafting (CABG) surgery have to wait 5-7 days for the effects of the drugs to wean off.
- Trial name
- NCT02201394
- Testing
- Ticagrelor loading dose, Aspirin loading dose, Ticagrelor maintenance dose
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Stable Coronary Artery Disease
A Pharmacodynamic Study With Ticagrelor in Hispanic Patients
The purpose of this study is to assess the pharmacodynamic effect of ticagrelor in Hispanic patients with stable coronary artery disease.
- Trial name
- NCT01523366
- Testing
- Ticagrelor, Clopidogrel
- Where
- 5 sites in United States
- Volunteers
- 53 people
- Sponsor
- AstraZeneca
Coronary Artery Disease
Standard Clopidogrel Versus Prasugrel Low Dose Therapy in Elderly Patients With Acute Coronary Syndrome
The elderly represent a growing segment of the coronary population treated by dual antiplatelet therapy for percutaneous coronary intervention (PCI).
- Trial name
- RESET ELDERLY (NCT01778842)
- Testing
- Clopidogrel, Prasugrel
- Where
- Italy
- Volunteers
- 68 people
- Sponsor
- Gennaro Sardella
Coronary Artery Disease
High Clopidogrel Dose Versus Prasugrel and Ticagrelor in High Reactive Stable Patients
Dual antiplatelet therapy with Aspirin and Clopidogrel for at least one year is essential in patients following an acute coronary syndrome (ACS) or percutaneous coronary intervention (PCI) with drug eluting stent(s) implantation.
- Trial name
- TRIPLETE RESET (NCT01543932)
- Testing
- Clopidogrel, Prasugrel, Ticagrelor
- Where
- Italy
- Volunteers
- 81 people
- Sponsor
- University of Roma La Sapienza
Coronary Arteriosclerosis
Antiplatelet Effect of Low Doses of Aspirin Taken Every 12 Hours in Patients Undergoing Coronary Artery Bypass Graft and/or Aortic Valve Surgery
This study is a randomized open label study that implies the administration of asprin according to three different regimens. The aims of the study are: to establish whether coronary artery bypass surgery and / or aortic valve…
- Trial name
- ASABYVALV (NCT01466452)
- Testing
- Aspirin
- Where
- Italy
- Volunteers
- 99 people
- Sponsor
- Centro Cardiologico Monzino
Coronary Artery Disease
Edoxaban in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy With Aspirin and Clopidogrel
It is not uncommon that patients requiring dual antiplatelet therapy (DAPT) also need to be treated with oral anticoagulant therapy, such as those with atrial fibrillation (AF).
- Trial name
- EDOX-APT (NCT02567461)
- Testing
- Edoxaban 60 mg, Edoxaban 30 mg, Clopidogrel 75 mg
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- University of Florida
Diabetes Mellitus, Type 2, Coronary Artery Disease
Ticagrelor With and Without Aspirin in Patients With Diabetes Mellitus
Recent studies have shown that withdrawing aspirin and maintaining P2Y12 inhibitor monotherapy for up to 12 months post-PCI, after a brief period of DAPT, reduces bleeding without increasing ischemic harm.
- Trial name
- OPTIMUS-7 (NCT04484259)
- Testing
- Ticagrelor monotherapy, Ticagrelor plus aspirin, Clopidogrel with aspirin
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- University of Florida
Bleeding, Tachycardia
Effect of Desmopressin on Platelet Function in CKD Patients on Antiplatelet Drug
Prolonged Collagen/Epinephrine - closure time (CEPI-CT) indicates platelet dysfunction in CKD patients taking antiplatelet agent.
- Conditions
- Bleeding, Tachycardia, Dyspnea
- Trial name
- NCT01841515
- Testing
- Desmopressin administration
- Where
- South Korea
- Volunteers
- 25 people
- Sponsor
- University of Ulsan
Dietary Exposure
Effect of Tomato Soffritto Intake on Biomarkers of Cardiovascular Disease in an Overweight and Obesity
The study is a prospective, controlled, randomized two-arm longitudinal crossover trial, performed in a single-centre. Hence, the investigators designed a clinical study aimed to investigate the effects of a daily intake of…
- Trial name
- FRITOCARD (NCT06161883)
- Testing
- Soffritto
- Where
- Spain
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Dual Antiplatelet Therapy, Platelet Reactivity
Is There a Transient Rebound Effect of Platelet Reactivity Following Cessation of Dual Antiplatelet Therapy With Ticagrelor - a Single Center Prospective Observational Trial
to assess whether cessation of 12 months DAPT regimen containing Ticagrelor results in a hyperreactive phase of platelet function
- Trial name
- NCT02808039
- Testing
- Platelet reactivity testing
- Where
- Israel
- Volunteers
- 60 people
- Sponsor
- Rabin Medical Center